Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Lancet. 2012 Nov 10;380(9854):1649-61. doi: 10.1016/S0140-6736(12)61272-0. Epub 2012 Sep 24.
Hypertension is the most prevalent comorbidity in individuals with chronic kidney disease. However, whether the association of the kidney disease measures, estimated glomerular filtration rate (eGFR) and albuminuria, with mortality or end-stage renal disease (ESRD) differs by hypertensive status is unknown.
We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and ESRD associated with eGFR and albuminuria in individuals with and without hypertension.
We analysed data for 45 cohorts (25 general population, seven high-risk, and 13 chronic kidney disease) with 1,127,656 participants, 364,344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts. All-cause mortality risk was 1·1-1·2 times higher in individuals with hypertension than in those without hypertension at preserved eGFR. A steeper relative risk gradient in individuals without hypertension than in those with hypertension at eGFR range 45-75 mL/min per 1·73 m(2) led to much the same mortality risk at lower eGFR. With a reference eGFR of 95 mL/min per 1·73 m(2) in each group to explicitly assess interaction, adjusted HR for all-cause mortality at eGFR 45 mL/min per 1·73 m(2) was 1·77 (95% CI 1·57-1·99) in individuals without hypertension versus 1·24 (1·11-1·39) in those with hypertension (p for overall interaction=0·0003). Similarly, for albumin-creatinine ratio of 300 mg/g (vs 5 mg/g), HR was 2·30 (1·98-2·68) in individuals without hypertension versus 2·08 (1·84-2·35) in those with hypertension (p for overall interaction=0·019). We recorded much the same results for cardiovascular mortality. The associations of eGFR and albuminuria with ESRD, however, did not differ by hypertensive status. Results for chronic kidney disease cohorts were similar to those for general and high-risk population cohorts.
Chronic kidney disease should be regarded as at least an equally relevant risk factor for mortality and ESRD in individuals without hypertension as it is in those with hypertension.
US National Kidney Foundation.
高血压是慢性肾脏病患者最常见的合并症。然而,肾脏疾病的衡量指标(估算肾小球滤过率[eGFR]和白蛋白尿)与死亡率或终末期肾病(ESRD)的相关性是否因高血压状态而异尚不清楚。
我们根据慢性肾脏病预后联盟的标准,对符合条件的研究进行了荟萃分析。数据传输和分析于 2011 年 3 月至 2012 年 6 月进行。我们使用 Cox 比例风险模型来估计 eGFR 和白蛋白尿与死亡率和 ESRD 相关的风险比(HR),分别在有和没有高血压的个体中进行。
我们分析了来自 45 个队列(25 个一般人群队列、7 个高危队列和 13 个慢性肾脏病队列)的数据,共纳入 1127656 名参与者,其中 364344 名患有高血压。在一般人群和高危人群中,无论是否患有高血压,低 eGFR 和高白蛋白尿均与死亡率相关。与 eGFR 正常的个体相比,高血压患者的全因死亡率高 1.1-1.2 倍。在 eGFR 范围为 45-75mL/min/1.73m2 的个体中,无高血压患者的相对风险梯度比高血压患者更陡峭,导致 eGFR 较低时的死亡率相当。在每组中以参考 eGFR 为 95mL/min/1.73m2 明确评估交互作用,无高血压患者的全因死亡率的调整 HR 为 eGFR 45mL/min/1.73m2 时为 1.77(95%CI 1.57-1.99),而高血压患者为 1.24(1.11-1.39)(p 对于整体交互作用=0.0003)。同样,对于白蛋白-肌酐比值为 300mg/g(vs 5mg/g),无高血压患者的 HR 为 2.30(1.98-2.68),而高血压患者为 2.08(1.84-2.35)(p 对于整体交互作用=0.019)。我们在心血管死亡率方面记录了大致相同的结果。然而,eGFR 和白蛋白尿与 ESRD 的相关性并不因高血压状态而异。慢性肾脏病队列的结果与一般人群和高危人群队列的结果相似。
慢性肾脏病在无高血压的个体中,至少与有高血压的个体一样,被视为死亡率和 ESRD 的同等重要的危险因素。
美国国家肾脏基金会。